Last 16,150 KRW
Change Today +850.00 / 5.56%
Volume 365.9K
068760 On Other Exchanges
As of 1:27 AM 03/3/15 All times are local (Market data is delayed by at least 15 minutes).

celltrion pharm inc (068760) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/23/15 - 18,600
52 Week Low
12/15/14 - 8,000
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CELLTRION PHARM INC (068760)

Related News

No related news articles were found.

celltrion pharm inc (068760) Related Businessweek News

No Related Businessweek News Found

celltrion pharm inc (068760) Details

Celltrion Pharm Inc., a pharmaceutical company, produces and sells biosimilars and over-the-counter drugs in South Korea. It offers hepatotonic, anti-inflammatory, antihistamine, respiratory apparatus, circulary system, digestive and stomachic, hormone/metabolic disease, antibiotics/antimycotic, nutrientia and tonic, immunology, oncology, and other drugs. The company also exports its products to South-East Asian countries, such as China, the Philippines, Vietnam, and Kazakhstan. It serves approximately 3800 customers, including university hospitals and general pharmacies. The company was founded in 1976 and is headquartered in Seoul, South Korea.

Founded in 1976

celltrion pharm inc (068760) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

celltrion pharm inc (068760) Key Developments

Celltrion Pharm Inc., Annual General Meeting, Mar 28, 2014

Celltrion Pharm Inc., Annual General Meeting, Mar 28, 2014., at 09:00 Korea Standard Time. Location: 706-1, Yeoksam-dong, Gangnam-gu, Seoul Tower, 6th Floor Kite. Agenda: To approve the Financial Statement; to approve the articles of incorporation to change some; to approve election of Directors; to approve director remuneration; and to approve stock option grants.

Celltrion In Talks For Controlling Stake Sale

Celltrion Pharm Inc. (KOSDAQ:A068760) said it is in talks with undisclosed potential buyers over its controlling stake sale. Celltrion said in a regulatory filing that Celltrion’s largest shareholder signed a contract with JP Morgan for the management of the planned stake sale and concrete talks are underway with potential buyers.

Celltrion Appoints Jpmorgan As Advisor On Possible Sale By Seo Jung-Jin

Celltrion, Inc. announced hiring JPMorgan Chase & Co. as advisor on the possible sale stake sale by Seo Jung-Jin, Founder of Celltrion in Celltrion, CelltrionHealthcare, Co., Ltd and Celltrion Pharm Inc. Celltrion is yet to figure out the number and the value of the deals required for the asset sales. Seo Jung-Jin said on April 16, 2013 that he will take his hands off the business he created in 2002, blaming speculative short selling against Celltrion. "I decided to sell my company to a multinational pharmaceutical company to make it a strong one that can guard off continuous suspicions and attacks by speculative investors," Seo Jung-Jin said in a statement.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
068760:KS 16,150.00 KRW +850.00

068760 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 068760.
View Industry Companies

Industry Analysis


Industry Average

Valuation 068760 Industry Range
Price/Earnings 98.8x
Price/Sales 3.4x
Price/Book 1.3x
Price/Cash Flow 68.2x
TEV/Sales 1.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELLTRION PHARM INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at